First Wave BioPharma, Inc. has had to navigate some choppy waters in the past few months but the US firm has pulled off something of a coup by bagging the rights to an old Sanofi compound for peanuts.
Key Takeaways
- Sanofi studied capeserod for neurological disorders almost 20 years ago
The drug in question is capeserod, a selective 5-HT4 receptor partial agonist which Sanofi originally evaluated almost a couple of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?